Acurx Pharmaceuticals has been granted a new patent by the Japanese Patent Office for its DNA polymerase IIIC inhibitors, which target the treatment of MRSA, VRE, and Anthrax infections. This patent is set to expire in December 2039, subject to extension, and represents a significant advancement in the ongoing development of their pre-clinical antibiotic candidate, ACX-375C.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.